Info 🌱 來自: Molecular biology-of-NSCLC METex14 Mt: 3-4% of ADCL, Mts lead to exon 14 skipping (ubiquitin-binding site) & persistent activation; a/w sarcomatoid carcinoma. Can be 2° to EGFR Mt. Sn to MET inhibitors (Nat Rev Clin Oncol 2020;17:569)